Trials / Completed
CompletedNCT03508609
Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
An Open-Label Exploratory Clinical Study to Evaluate the Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction (CMD) and Without Obstructive Coronary Artery Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Lisata Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial will explore the safety and effect of GCSF-mobilized autologous ex vivo selected CD34 cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single intracoronary infusion of CLBS16.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CLBS16 | GCSF-mobilized autologous CD34 cells |
Timeline
- Start date
- 2018-04-19
- Primary completion
- 2019-12-10
- Completion
- 2020-05-05
- First posted
- 2018-04-26
- Last updated
- 2021-01-08
- Results posted
- 2021-01-08
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03508609. Inclusion in this directory is not an endorsement.